Immunotherapy and targeted therapy before surgery for advanced skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (EGFR inhibitor)—given before surgery for locally advanced squamous cell skin cancer. The goal is to shrink the tumor enough to make surgery safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of skin cancer called squamous cell carcinoma that is locally advanced—meaning it's grown deeply into nearby tissues but hasn't spread to distant organs.
- You are at least 18 years old and can follow the treatment plan and return for checkups.
- Your tumor can be measured (at least 1 cm across) and you have tissue from a previous biopsy available.
- Your blood counts, kidney function, and liver function are within a certain range (your doctor will check this).
- You haven't had immunotherapy or an EGFR-blocking drug before for this cancer or any other cancer.
- You do not have an active autoimmune disease that requires strong immune-suppressing medications, and you are not a transplant recipient.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
This trial tests combining a skin cream (imiquimod), a laser treatment, and an immunotherapy drug (cemiplimab) before surgery for high-risk basal cell carcinoma. The goal is to see if this combination shrinks tumors enough to make surgery less disfiguring or damaging to nearby functions.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
This Phase 2 trial tests pembrolizumab (an immune therapy) given before surgery to see if it can help control high-risk invasive cutaneous squamous cell carcinoma. The goal is to improve outcomes by treating cancer earlier and then following with standard surgery and radiation if needed.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
Hear when a new Locally Advanced Cutaneous Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.